BRAF

General Information

The BRAF gene is frequently mutated in human melanomas, with mutations seen in 35-50% of cases. Mutations lead to constitutive activation and aberrant signalling, and subsequent malignant behaviour. Drugs that treat those cancers by inhibiting BRAF are now licensed for use in metastatic disease.

• Paraffin block from biopsy, resection or cell block
• 4-6μm on uncharged slides

Please note tissue handling, tissue fixation, time between cutting and staining and excessive drying can lead to loss of expression. Fixatives containing alcohol should not be used and use of Bouin’s fixative will preclude testing by FISH methods.

A copy of the original Pathology report where possible.

BRAF Request Form